CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Changes Stockholders' Deficit

Consolidated Statements of Changes Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Preferred Stock Series C Convertible Preferred Stock	Preferred Stock	Common Stock Series C Convertible Preferred Stock	Common Stock Private Equity Offering	Common Stock	Treasury Stock	Additional Paid-in Capital Series C Convertible Preferred Stock	Additional Paid-in Capital Private Equity Offering	Additional Paid-in Capital	Accumulated Deficit	Private Equity Offering	Total
Beginning balance at May. 31, 2022					$ 720				$ 671,013	$ (766,131)		$ (94,398)
Beginning balance (shares) at May. 31, 2022		35			720,028	443
Stock issued for compensation					$ 1				344			345
Stock issued for compensation (in shares)					879
Stock issued for private offerings				$ 85				$ 17,459			$ 17,544
Stock issued for private offerings (in shares)				85,378
Issuance costs related to stock issued for private offerings									(6,289)			(6,289)
Conversion of preferred stock to common stock			$ 1				$ (1)
Conversion of preferred stock to common stock (in shares)	(1)		1,136
Warrant exercises					$ 1				263			264
Warrant exercises (in shares)					657
Deemed dividend paid in common stock due to down round provision, recorded in additional paid-in capital					$ 5				(5)
Deemed dividend paid in common stock due to down round provision recorded in additional paid-in capital (in shares)					4,620
Dividends accrued on Series C and D convertible preferred stock									(384)			(384)
Reclassification of warrants from liability to equity classified									8,601			8,601
Stock-based compensation									996			996
Reclassification of prior period preferred stock dividends									(4,265)	4,265
Net loss										(20,991)		(20,991)
Ending balance at Aug. 31, 2022					$ 813				687,732	(782,857)		(94,312)
Ending balance (shares) at Aug. 31, 2022		34			812,698	443
Beginning balance at May. 31, 2022					$ 720				671,013	(766,131)		(94,398)
Beginning balance (shares) at May. 31, 2022		35			720,028	443
Loss on induced conversion												638
Net loss												(47,486)
Ending balance at Nov. 30, 2022					$ 825				692,558	(809,352)		(115,969)
Ending balance (shares) at Nov. 30, 2022		34			825,279	443
Beginning balance at Aug. 31, 2022					$ 813				687,732	(782,857)		(94,312)
Beginning balance (shares) at Aug. 31, 2022		34			812,698	443
Issuance of stock for convertible note repayment					$ 2				498			500
Issuance of stock for convertible note repayment (in shares)					1,822
Loss on induced conversion									638			638
Stock issued for compensation									310			310
Stock issued for compensation (in shares)					765
Exercise of warrants, net of issuance costs					$ 10				2,123			2,133
Exercise of warrants, net of issuance costs (in shares)					9,652
Make-whole shares related to private warrant exchange (in shares)					23
Dividend paid in common stock upon conversion of Series C convertible preferred stock ($0.50 per share)									159			159
Dividend paid in common stock upon conversion of Series C convertible preferred stock ($0.50 per share) (in shares)					319
Dividends accrued on Series C and D convertible preferred stock									(369)			(369)
Stock-based compensation									1,467			1,467
Net loss										(26,495)		(26,495)
Ending balance at Nov. 30, 2022					$ 825				692,558	(809,352)		(115,969)
Ending balance (shares) at Nov. 30, 2022		34			825,279	443
Beginning balance at May. 31, 2023					$ 919				731,270	(841,690)		(109,501)
Beginning balance (shares) at May. 31, 2023		34			919,053	443
Issuance of stock for convertible note repayment					$ 8				1,492			1,500
Issuance of stock for convertible note repayment (in shares)					8,661
Loss on induced conversion									2,004			2,004
Warrants issued in note offering									170			170
Stock issued for compensation					$ 1				154			155
Stock issued for compensation (in shares)					686
Warrant exercises					$ 3				297			300
Warrant exercises (in shares)					3,000
Dividends accrued on Series C and D convertible preferred stock									(373)			(373)
Reclassification of warrants from liability to equity classified									79			79
Stock-based compensation									348			348
Net loss										(11,571)		(11,571)
Ending balance at Aug. 31, 2023					$ 931				735,441	(853,261)		(116,889)
Ending balance (shares) at Aug. 31, 2023		34			931,400	443
Beginning balance at May. 31, 2023					$ 919				731,270	(841,690)		(109,501)
Beginning balance (shares) at May. 31, 2023		34			919,053	443
Loss on induced conversion												2,640
Net loss												(21,134)
Ending balance at Nov. 30, 2023					$ 971				747,472	(862,824)		(114,381)
Ending balance (shares) at Nov. 30, 2023		34			971,286	443
Beginning balance at Aug. 31, 2023					$ 931				735,441	(853,261)		(116,889)
Beginning balance (shares) at Aug. 31, 2023		34			931,400	443
Issuance of stock for convertible note repayment					$ 4				496			500
Issuance of stock for convertible note repayment (in shares)					3,535
Loss on induced conversion									636			636
Warrants issued in note offering									10			10
Note conversion					$ 14				4,379			4,393
Note conversion (in shares)					14,339
Stock issued for compensation					$ 1				97			98
Stock issued for compensation (in shares)					559
Stock issued for private offerings					$ 21				6,307			6,328
Stock issued for private offerings (in shares)					21,453
Dividends accrued on Series C and D convertible preferred stock									(368)			(368)
Stock-based compensation									474			474
Net loss										(9,563)		(9,563)
Ending balance at Nov. 30, 2023					$ 971				$ 747,472	$ (862,824)		$ (114,381)
Ending balance (shares) at Nov. 30, 2023		34			971,286	443